The T2DM subjects with glycosylated hemoglobin A1c ( HbA1c ) between 7 % and 10 % and aged between 18 years and 75 years were enrolled and randomized to the alogliptin group and the placebo group in 1 : 1 ratio with 16 weeks treatment .